KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.
The association between Staphylococcus aureus and subsequent bronchiectasis in children with cystic fibrosis
One time quantitative PCR detection of Pseudomonas aeruginosa to discriminate intermittent from chronic infection in cystic fibrosis
Quantifying fluctuation in glucose levels to identify early changes in glucose homeostasis in cystic fibrosis.
Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients
Hypoglycaemia (low blood sugar) in cystic fibrosis: an analysis of single centre adult cystic fibrosis clinic
Differences between WHO AND CDC early growth measurements in the assessment of Cystic Fibrosis clinical outcomes.
